BRPI1011505A2 - formas de pró-drogas de inibidores de quinase e sua aplicação em terapia - Google Patents
formas de pró-drogas de inibidores de quinase e sua aplicação em terapiaInfo
- Publication number
- BRPI1011505A2 BRPI1011505A2 BRPI1011505A BRPI1011505A BRPI1011505A2 BR PI1011505 A2 BRPI1011505 A2 BR PI1011505A2 BR PI1011505 A BRPI1011505 A BR PI1011505A BR PI1011505 A BRPI1011505 A BR PI1011505A BR PI1011505 A2 BRPI1011505 A2 BR PI1011505A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapy
- application
- kinase inhibitor
- prodrug forms
- inhibitor prodrug
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ57549009 | 2009-03-11 | ||
| NZ57945809 | 2009-09-02 | ||
| NZ58117009 | 2009-11-12 | ||
| PCT/NZ2010/000040 WO2010104406A1 (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011505A2 true BRPI1011505A2 (pt) | 2016-03-22 |
Family
ID=42728538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011505A BRPI1011505A2 (pt) | 2009-03-11 | 2010-03-11 | formas de pró-drogas de inibidores de quinase e sua aplicação em terapia |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9073916B2 (pt) |
| EP (2) | EP2406262B1 (pt) |
| JP (1) | JP5793428B2 (pt) |
| KR (1) | KR20110130468A (pt) |
| CN (2) | CN105541836A (pt) |
| AU (1) | AU2010221818A1 (pt) |
| BR (1) | BRPI1011505A2 (pt) |
| CA (1) | CA2754808C (pt) |
| IL (1) | IL214626A0 (pt) |
| MX (1) | MX2011009034A (pt) |
| NZ (2) | NZ620000A (pt) |
| RU (1) | RU2011141121A (pt) |
| WO (1) | WO2010104406A1 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| TW200803892A (en) | 2005-11-04 | 2008-01-16 | Wyeth Corp | Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| DK2310011T3 (da) | 2008-06-17 | 2013-10-14 | Wyeth Llc | Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin |
| KR101434009B1 (ko) | 2008-08-04 | 2014-08-25 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
| US9073916B2 (en) | 2009-03-11 | 2015-07-07 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
| US9211291B2 (en) | 2009-04-06 | 2015-12-15 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| MX336332B (es) * | 2009-09-02 | 2016-01-15 | Auckland Uniservices Ltd | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. |
| CN102558185B (zh) * | 2010-12-09 | 2016-02-10 | 中国科学院上海药物研究所 | 吡啶并吡咯三嗪化合物、其制备方法和用途 |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| US9353062B2 (en) * | 2012-04-04 | 2016-05-31 | Hangzhouderenyucheng Biotechnology Ltd | Substituted quinolines as bruton's tyrosine kinases inhibitors |
| CN105796562A (zh) * | 2012-09-10 | 2016-07-27 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| CN105796569A (zh) * | 2012-09-10 | 2016-07-27 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| CN103655576A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103664797A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103724349A (zh) * | 2012-10-11 | 2014-04-16 | 韩冰 | 一类治疗脑性瘫痪的化合物及其用途 |
| CN102952095A (zh) * | 2012-10-19 | 2013-03-06 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法 |
| CN103787986A (zh) * | 2012-10-31 | 2014-05-14 | 韩冰 | 一类治疗干眼症的化合物及其用途 |
| CN103784456A (zh) * | 2012-10-31 | 2014-05-14 | 韩冰 | 一类治疗干眼症的化合物及其用途 |
| CN103804304A (zh) * | 2012-11-01 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804305A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103804306A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
| SG11201506972PA (en) * | 2013-03-14 | 2015-10-29 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| US10072018B2 (en) | 2013-04-17 | 2018-09-11 | Biopharma Works | Compounds for treatment of pain |
| US9487531B2 (en) | 2013-04-17 | 2016-11-08 | BioPharma Works LLC | Compounds for treatment of pain |
| EP3022186B1 (en) * | 2013-07-18 | 2020-02-26 | Shanghai Fochon Pharmaceutical Co. Ltd | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals |
| US10507210B2 (en) | 2014-12-03 | 2019-12-17 | Auckland Uniservices Limited | Kinase inhibitor prodrug for the treatment of cancer |
| WO2017004005A1 (en) * | 2015-06-29 | 2017-01-05 | Ontogenesis, Llc | N-acylalkyl prodrugs of multi-tyrosine kinase inhibitors and methods of use |
| CN110809576B (zh) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | Fgfr激酶抑制剂和药物用途 |
| CN107569491A (zh) * | 2017-08-30 | 2018-01-12 | 杭州科兴生物化工有限公司 | 一种星孢菌素类化合物的应用 |
| AU2018330171A1 (en) | 2017-09-08 | 2020-03-12 | The Regents Of The University Of Colorado, A Body Corporate | Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers |
| WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
| AU2019227823B2 (en) * | 2018-02-28 | 2024-12-12 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| WO2021003339A1 (en) | 2019-07-03 | 2021-01-07 | The Regents Of The University Of Colorado, A Body Corporate | Amp-activated protein kinase inhibitors and methods of making and using the same |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| WO2022006412A2 (en) | 2020-07-02 | 2022-01-06 | The Regents Of The University Of Colorado, A Body Corporate | Conjugates of ampk inhibitors and protac degraders and related uses |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0850224B1 (en) | 1995-08-18 | 2003-04-09 | Auckland Uniservices Limited | Radiation-activated cytotoxin therapy |
| DE69710712T3 (de) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | Umkehrbare inhibitoren von tyrosin kinasen |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6355636B1 (en) | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| RU2005135329A (ru) | 2003-04-16 | 2006-08-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Замещенные 7-азахиназолины |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| AP2204A (en) | 2004-05-06 | 2011-02-07 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides. |
| GB0421294D0 (en) | 2004-09-24 | 2004-10-27 | Angiogene Pharm Ltd | Bioreductively-activated prodrugs |
| DK1948180T3 (da) * | 2005-11-11 | 2013-05-27 | Boehringer Ingelheim Int | Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| WO2008039087A2 (en) | 2006-09-29 | 2008-04-03 | Auckland Uniservices Limited | Indoline derivatives and uses thereof |
| WO2008151253A1 (en) * | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| US9073916B2 (en) | 2009-03-11 | 2015-07-07 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
-
2010
- 2010-03-11 US US13/138,429 patent/US9073916B2/en active Active
- 2010-03-11 NZ NZ620000A patent/NZ620000A/en not_active IP Right Cessation
- 2010-03-11 BR BRPI1011505A patent/BRPI1011505A2/pt not_active IP Right Cessation
- 2010-03-11 NZ NZ595206A patent/NZ595206A/en not_active IP Right Cessation
- 2010-03-11 KR KR1020117023889A patent/KR20110130468A/ko not_active Ceased
- 2010-03-11 JP JP2011553972A patent/JP5793428B2/ja active Active
- 2010-03-11 EP EP10751067.9A patent/EP2406262B1/en active Active
- 2010-03-11 CN CN201610031117.5A patent/CN105541836A/zh active Pending
- 2010-03-11 EP EP16150071.5A patent/EP3031807A1/en not_active Withdrawn
- 2010-03-11 AU AU2010221818A patent/AU2010221818A1/en not_active Abandoned
- 2010-03-11 CA CA2754808A patent/CA2754808C/en active Active
- 2010-03-11 MX MX2011009034A patent/MX2011009034A/es unknown
- 2010-03-11 RU RU2011141121/04A patent/RU2011141121A/ru not_active Application Discontinuation
- 2010-03-11 WO PCT/NZ2010/000040 patent/WO2010104406A1/en not_active Ceased
- 2010-03-11 CN CN2010800114500A patent/CN102348708A/zh active Pending
-
2011
- 2011-08-11 IL IL214626A patent/IL214626A0/en unknown
-
2015
- 2015-06-04 US US14/731,309 patent/US20160002222A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012520295A (ja) | 2012-09-06 |
| EP3031807A1 (en) | 2016-06-15 |
| EP2406262A1 (en) | 2012-01-18 |
| EP2406262B1 (en) | 2016-02-17 |
| AU2010221818A1 (en) | 2011-10-06 |
| JP5793428B2 (ja) | 2015-10-14 |
| MX2011009034A (es) | 2011-09-22 |
| US9073916B2 (en) | 2015-07-07 |
| US20120077811A1 (en) | 2012-03-29 |
| RU2011141121A (ru) | 2013-04-20 |
| WO2010104406A1 (en) | 2010-09-16 |
| EP2406262A4 (en) | 2012-06-20 |
| CN102348708A (zh) | 2012-02-08 |
| CA2754808C (en) | 2019-01-08 |
| NZ595206A (en) | 2014-02-28 |
| NZ620000A (en) | 2015-07-31 |
| WO2010104406A8 (en) | 2011-10-06 |
| CA2754808A1 (en) | 2010-09-16 |
| US20160002222A1 (en) | 2016-01-07 |
| IL214626A0 (en) | 2011-09-27 |
| KR20110130468A (ko) | 2011-12-05 |
| CN105541836A (zh) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011505A2 (pt) | formas de pró-drogas de inibidores de quinase e sua aplicação em terapia | |
| NL300891I2 (nl) | Lotilaner en zouten daarvan | |
| BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
| EP2344481A4 (en) | VIRUS AND FUNGI | |
| SMT201600430B (it) | Inibitori di chinasi e loro uso nel trattamento del cancro | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| CY2015013I1 (el) | Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων | |
| HRP20170936T1 (hr) | Alkilamido spojevi i njihova uporaba | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| DK3417701T3 (da) | Genmodificerede mus og indpodning | |
| BRPI0913594A2 (pt) | filtro rosqueável com rosca externas e métodos | |
| ZA201101586B (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
| DK2185552T3 (da) | Dipeptoid-prodrugs og anvendelse heraf | |
| SMT201400164B (it) | Morfolino pirimidine e loro uso in terapia | |
| BRPI0817890A2 (pt) | Folha e artigo | |
| DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
| BR112012005774B8 (pt) | uso de um inibidor de quinase antiangiogênico no tratamento de câncer | |
| IL207415A0 (en) | Protein kinase inhibitors and use thereof | |
| BRPI0816789A2 (pt) | Goji e inflamação | |
| DK2358710T3 (da) | AKT- og P70-S6-kinaseinhibitorer | |
| DK2235002T3 (da) | 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer | |
| BRPI0920850A2 (pt) | novos compostos e sua utilização | |
| ZA201003420B (en) | Protein kinase inhibitors and use thereof | |
| BRPI0807421A2 (pt) | Microrganismo recombinante | |
| BR112012004720A2 (pt) | inibidores de cinase, formas de profármaco dos mesmos e seu uso em terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |